Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02025816 · ClinicalTrials.gov registry record
RNAseq Analysis of Microbial Gene Expression in Necrotizing Soft Tissue Infections
A clinical trial, sponsored by Texas Tech University Health Sciences Center.
- Completed
- Registry status
- 35
- Enrollment target
NCT02025816 is a clinical trial that has completed, run by Texas Tech University Health Sciences Center. The registered enrollment target is 35 participants.
The verdict
NCT02025816 has completed, sponsored by Texas Tech University Health Sciences Center.
- COMPLETED
- Registry status
- 35 participants
- Enrollment target
Study Summary
Hypothesis: We hypothesize that RNAseq will allow us to learn more about the causative agents of necrotizing soft tissue infections (NSTI) and risk factors involved in acquiring these devastating infections Tissue biopsies will be obtained from consented patients admitted with NSTI. Biopsies will be used for standard clinical analysis of bacterial species present or stored for later RNA sequencing. RNA sequencing will identify bacteria that are present within the infection site that may not be detected using standard culture techniques as well as reveal bacterial gene expression profiles within the NSTI site. Medical charts will also be reviewed for basic patient information as well as wound care management practices. We hope to identify bacterial species commonly present in these types of infections as well as risk factors predisposing individuals to NSTI's.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2013-12 |
| Est. Completion | 2019-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02025816
The ClinicalTrials.gov registry entry for NCT02025816 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas Tech University Health Sciences Center, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02025816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02025816 about?
NCT02025816 is a clinical study titled "RNAseq Analysis of Microbial Gene Expression in Necrotizing Soft Tissue Infections". Hypothesis: We hypothesize that RNAseq will allow us to learn more about the causative agents of necrotizing soft tissue infections (NSTI) and risk factors involved in acquiring these devastating infections Tissue biopsies will be obtained from consented patients admitted with NSTI. Biopsies will b...
What is the current status of trial NCT02025816?
This trial is currently completed. The enrollment target is 35 participants. The study started on 2013-12. Estimated completion is 2019-06.
Who is sponsoring clinical trial NCT02025816?
This trial is sponsored by Texas Tech University Health Sciences Center, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.